![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
DS Sonnichsen, Q Liu, EG Schuetz, JD Schuetz, A Pappo and MV Relling
Pharmaceutical Department, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Formation of 6 alpha-hydroxypaclitaxel has been described as the primary biotransformation pathway for paclitaxel in vitro and in vivo, with additional formation of two other "minor" metabolites. Using a large group (n = 49) of human liver microsomes, and P450s heterologously expressed in cell lines, our aims were to elucidate the P450s responsible for and investigate variability in paclitaxel metabolite formation. Four metabolites of paclitaxel (6 alpha- hydroxypaclitaxel, metabolites B, C and A) were formed in vitro, via CYP2C8, 3A4, 3A4 and both 2C8 and 3A4, respectively. Although 6 alpha- hydroxypaclitaxel was predominant in the majority of livers, metabolites B and C (formed by CYP3A4) were predominant in 11/49 and 2/49 livers, respectively. Predominance of metabolite B over 6 alpha- hydroxypaclitaxel was more likely in liver microsomes from donors known to be exposed to phenobarbital (P = .009), and tended to be more likely in diseased vs. normal livers (P = .047). Formation rates for 6 alpha- hydroxypaclitaxel, A, B, and C were lower in diseased liver vs. normal liver (P < .001). Rates of formation of metabolites B and C were highly correlated with each other (r2 = .91; P < .001) and with midazolam 4- hydroxylation (r2 = .87 & 0.86, respectively; P < .001). Inhibitor experiments suggest that typical CYP3A substrates/inhibitors (e.g., cyclosporin, epipodophyllotoxins) may significantly interact with paclitaxel in vivo. In a single patient in whom plasma samples were measured on two occasions, metabolite A (the dihydroxylate) was predominant, and systemic clearance of paclitaxel was lower in a course administered 1 day vs. 6 wk after a course of fluconazole therapy. We report that 6 alpha-hydroxypaclitaxel, formed via CYP2C8, is not the predominant paclitaxel metabolite in all individuals, and that CYP3A4 catalytic activity is important to overall paclitaxel metabolism in humans.
This article has been cited by other articles:
|
|
 |
|
  B. Hosten, C. Abbara, B. Petit, A. Dauvin, F. Bourasset, R. Farinotti, P. Gonin, and L. Bonhomme-Faivre Effect of Interleukin-2 Pretreatment on Paclitaxel Absorption and Tissue Disposition after Oral and Intravenous Administration in Mice Drug Metab. Dispos., August 1, 2008; 36(8): 1729 - 1735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Henningsson, S. Marsh, W. J. Loos, M. O. Karlsson, A. Garsa, K. Mross, S. Mielke, L. Vigano, A. Locatelli, J. Verweij, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel Clin. Cancer Res., November 15, 2005; 11(22): 8097 - 8104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Pang MODELING OF INTESTINAL DRUG ABSORPTION: ROLES OF TRANSPORTERS AND METABOLIC ENZYMES (FOR THE GILLETTE REVIEW SERIES) Drug Metab. Dispos., December 1, 2003; 31(12): 1507 - 1519. [Full Text] [PDF]
|
|
|
|
|
|
D. Tam, H. Sun, and K. S. Pang INFLUENCE OF P-GLYCOPROTEIN, TRANSFER CLEARANCES, AND DRUG BINDING ON INTESTINAL METABOLISM IN CACO-2 CELL MONOLAYERS OR MEMBRANE PREPARATIONS: A THEORETICAL ANALYSIS Drug Metab. Dispos., October 1, 2003; 31(10): 1214 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.M.F. Kruijtzer, J.H. Beijnen, and J.H.M. Schellens Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview Oncologist, December 1, 2002; 7(6): 516 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Arora, M. L. Cate, C. Ghosh, and P. L. Iversen Phosphorodiamidate Morpholino Antisense Oligomers Inhibit Expression of Human Cytochrome P450 3A4 and Alter Selected Drug Metabolism Drug Metab. Dispos., July 1, 2002; 30(7): 757 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-Q. Li, A. Bjorkman, T. B. Andersson, M. Ridderstrom, and C. M. Masimirembwa Amodiaquine Clearance and Its Metabolism to N-Desethylamodiaquine Is Mediated by CYP2C8: A New High Affinity and Turnover Enzyme-Specific Probe Substrate J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 399 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Advani, G. A. Fisher, B. L. Lum, J. Hausdorff, J. Halsey, M. Litchman, and B. I. Sikic A Phase I Trial of Doxorubicin, Paclitaxel, and Valspodar (PSC 833), a Modulator of Multidrug Resistance Clin. Cancer Res., May 1, 2001; 7(5): 1221 - 1229. [Abstract] [Full Text]
|
|
|
|
|
|
T. Komatsu, H. Yamazaki, N. Shimada, M. Nakajima, and T. Yokoi Roles of Cytochromes P450 1A2, 2A6, and 2C8 in 5-Fluorouracil Formation from Tegafur, an Anticancer Prodrug, in Human Liver Microsomes Drug Metab. Dispos., April 13, 2001; 28(12): 1457 - 1463. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. S. Cunha, M. L. Reguly, U. Graf, and H. H. R. de Andrade Taxanes: the genetic toxicity of paclitaxel and docetaxel in somatic cells of Drosophila melanogaster Mutagenesis, January 1, 2001; 16(1): 79 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Britten, S. D. Baker, L. J. Denis, T. Johnson, R. Drengler, L. L. Siu, K. Duchin, J. Kuhn, and E. K. Rowinsky Oral Paclitaxel and Concurrent Cyclosporin A: Targeting Clinically Relevant Systemic Exposure to Paclitaxel Clin. Cancer Res., September 1, 2000; 6(9): 3459 - 3468. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. M. Malingre, J. M. M. Terwogt, J. H. Beijnen, H. Rosing, F. J. Koopman, O. van Tellingen, K. Duchin, W. W. T. B. Huinink, M. Swart, J. Lieverst, et al. Phase I and Pharmacokinetic Study of Oral Paclitaxel J. Clin. Oncol., June 12, 2000; 18(12): 2468 - 2475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Blanco, P. L. Harrison, W. E. Evans, and M. V. Relling Human Cytochrome P450 Maximal Activities In Pediatric versus Adult Liver Drug Metab. Dispos., April 1, 2000; 28(4): 379 - 382. [Abstract] [Full Text]
|
|
|
|
|
|
V. E. Kostrubsky, V. Ramachandran, R. Venkataramanan, K. Dorko, J. E. Esplen, S. Zhang, J. F. Sinclair, S. A. Wrighton, and S. C. Strom The Use of Human Hepatocyte Cultures to Study the Induction of Cytochrome P-450 Drug Metab. Dispos., August 1, 1999; 27(8): 887 - 894. [Abstract] [Full Text]
|
|
|
|
|
|
M. H. Woo, M. V. Relling, D. S. Sonnichsen, G. K. Rivera, C. B. Pratt, C.-H. Pui, W. E. Evans, and A. S. Pappo Phase I Targeted Systemic Exposure Study of Paclitaxel in Children with Refractory Acute Leukemias Clin. Cancer Res., March 1, 1999; 5(3): 543 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Felix, A. H. Walker, B. J. Lange, T. M. Williams, N. J. Winick, N.-K. V. Cheung, B. D. Lovett, P. C. Nowell, I. A. Blair, and T. R. Rebbeck Association of CYP3A4 genotype with treatment-related leukemia PNAS, October 27, 1998; 95(22): 13176 - 13181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Fischer, A. Rodríguez-Gascón, F. Heitz, R. Tynes, C. Hauck, D. Cohen, and A. E. M. Vickers The Multidrug Resistance Modulator Valspodar (PSC 833) Is Metabolized by Human Cytochrome P450 3A. Implications for Drug-Drug Interactions and Pharmacological Activity of the Main Metabolite Drug Metab. Dispos., August 1, 1998; 26(8): 802 - 811. [Abstract] [Full Text]
|
|
|
|
|
|
B. Monsarrat, E. Chatelut, I. Royer, P. Alvinerie, J. Dubois, A. Dezeuse, H. Roché, S. Cros, M. Wright, and P. Canal Modification of Paclitaxel Metabolism in a Cancer Patient by Induction of Cytochrome P450 3A4 Drug Metab. Dispos., March 1, 1998; 26(3): 229 - 233. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. F. Lam, C. J. Chan, and J. G Kuhn Review : Pharmacokinetics and pharmacodynamics of the taxanes Journal of Oncology Pharmacy Practice, June 1, 1997; 3(2): 76 - 93. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
